Iguratimod CAS NO.123663-49-0

Iguratimod Basic information
Product Name:    Iguratimod
Synonyms:    IGURATIMOD;iguratimod( R&D);T 614;N-[7-methanesulfonamido-4-oxo-6-(phenoxy)chromen-3-yl]formamide;3-(Formylamino)-7-(methylsulfonylamino)-6-phenoxy-4H-1-benzopyran-4-one;N-[3-(Formylamino)-4-oxo-6-phenoxy-4H-1-benzopyran-7-yl]methanesulfonamide;IguratiMod (T 614);N-(7-(MethylsulfonaMido)-4-oxo-6-phenoxy-4H-chroMen-3-yl)forMaMide
CAS:    123663-49-0
MF:    C17H14N2O6S
MW:    374.37
EINECS:    808-127-0
Product Categories:    Pharmaceutical intermediate;Pharmaceuticals;API;123663-49-0
Mol File:    123663-49-0.mol

Iguratimod Chemical Properties
Melting point     238.0 to 242.0 °C
Boiling point     580.6±60.0 °C(Predicted)
density     1.52±0.1 g/cm3(Predicted)
storage temp.     under inert gas (nitrogen or Argon) at 2-8°C
solubility     DMSO (Slightly)
pka    5.58±0.20(Predicted)
form     Solid
color     White to Off-White
Safety Information
HS Code     2935.90.9500
MSDS Information
Iguratimod Usage And Synthesis
Description    
In August 2011, China’s State FDA approved Simcere Pharmaceutical Group’s new drug application for iguratimod (T-614), a disease modifying anti-rheumatic drug (DMARD) for the treatment of rheumatoid arthritis (RA). Preclinical in vivo studies indicated that iguratimod was effective in an established adjuvant-induced arthritis model (ED40=3.6 mg/kg) in rats and also efficacious in a type II collagen-induced arthritis model in DBA/1J mice at 30 mg and 100 mg/kg.

Originator    Toyama (Japan)
Uses    Iguratimod acts as an anti-inflammatory agent, used primarily in the treatment of rheumatoid arthritis.
Definition    ChEBI: Iguratimod is an organic molecular entity.
Brand name    Iremod
Clinical Use    Iguratimod, which was discovered by Toyama Pharmaceuticals and jointly co-developed with Eisai in Japan, was approved by the PMDA (Pharmaceuticals and Medical Devices Agency) of Japan on June 29, 2012 for the treatment of rheumatoid arthritis. This drug was also independently developed by Simcere Pharmaceutical Group and is marked as Iremod® in China. The drug exhibited inhibitory effects on granuloma inflammation, and was shown to be efficacious for the prevention of joint destruction in adjuvant arthritis.